Baxter posts strong Q4
This article was originally published in Scrip
Baxter posted strong sales and earnings figures for both the fourth quarter and full-year 2009, increasing its fourth-quarter bottom line despite taking a $56 million hit during the period from optimising its manufacturing and business operations.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.